Intralesional Injection of Ethanolamine Oleate Alone or Mixed with Bupivacaine in Oral Venous Malformation (Randomized Controlled Trial)
Not Applicable
- Conditions
- Oral Health
- Registration Number
- PACTR202209738652499
- Lead Sponsor
- Oral and Maxillofacial Surgery Department Faculty of Dentistry Alexandria University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Other
- Sex
- All
- Target Recruitment
- 16
Inclusion Criteria
Patients suffering from oral vascular malformations with a size of 2- 4 cm
Exclusion Criteria
High flow vascular malformations.
Patient’s medication interfering with coagulation and wound healing(e.g., steroids, bisphosphonates, anticoagulants) or specific states preventing the use of EAO (e.g., pregnancy, lactation).
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie ethanolamine oleate's efficacy in treating oral venous malformations?
How does the combination of ethanolamine oleate and bupivacaine compare to standard-of-care treatments for oral venous malformations in terms of effectiveness and safety?
Are there specific biomarkers that can predict patient response to intralesional ethanolamine oleate therapy in oral venous malformations?
What are the potential adverse events associated with intralesional ethanolamine oleate and bupivacaine injections in oral venous malformations, and how can they be managed?
What other compounds or combination therapies are being explored for the treatment of oral venous malformations alongside ethanolamine oleate?